En poursuivant votre navigation sur ce site, vous acceptez le dépôt de cookies dans votre navigateur. (En savoir plus)
Portail > Offres > Offre UMR5535-GUIBOS-001 - Post-doctorant (H/F) en onco-hématologie - M/F

Post-doc in onco-hematology

This offer is available in the following languages:
Français - Anglais

Date Limite Candidature : mardi 19 juillet 2022

Assurez-vous que votre profil candidat soit correctement renseigné avant de postuler. Les informations de votre profil complètent celles associées à chaque candidature. Afin d’augmenter votre visibilité sur notre Portail Emploi et ainsi permettre aux recruteurs de consulter votre profil candidat, vous avez la possibilité de déposer votre CV dans notre CVThèque en un clic !

General information

Reference : UMR5535-GUIBOS-001
Date of publication : Tuesday, June 28, 2022
Type of Contract : FTC Scientist
Contract Period : 24 months
Expected date of employment : 1 October 2022
Proportion of work : Full time
Remuneration : gross monthly salary between 2690€ and 3821€ according to experience
Desired level of education : PhD
Experience required : Indifferent


Acute Myeloid Leukemias (AML) are severe hematological malignancies with dismal prognosis. Our team has been interested for long in the role of SUMOylation in AML response to therapies. SUMOylation is a post-translational modification of the Ubiquitin Family, which regulates the function and fate of thousands of cellular proteins. In particular, SUMOylation plays important roles in the regulation of gene expression through the modification of many chromatin-bound proteins. Using various preclinical models, we have shown that the targeting of SUMOylation constitutes a promising new therapeutic approach in AML.


Using CRISPR-Cas9 screens as well as various genomic and proteomic approaches, the candidate will delineate the molecular basis of AML sensitivity to the inhibition of SUMOylation, in particular with clinically relevant molecules such as TAK-981, a first in class SUMOylation inhibitor. The experiments will be carried out in AML cells lines but also AML patient cells and different in vivo models.


Candidate should hold a PhD degree in biological sciences. An expertise in onco-hematology with experience in cytometry and mouse models would be ideal although all relevant profiles will be studies. Experience in CRISPR/Cas9 screens and/or bioinformatic analysis of sequencing data would be appreciated. The candidate should be proficient in English.

Work Context

The Ubiquitin Family in Hematologic Malignancies group is one of the 18 teams of the Institut de Génétique Moléculaire de Montpellier (IGMM). IGMM is a public plurithematic institute in Biology and Health Research founded in 1993. This Institute conducts fundamental research of excellence that is relevant to molecular and cellular medicine, with a particular emphasis on cancer and specific infectious and genetic diseases.
IGMM brings together more than 220 people: researchers, technicians and students, organised into 18 research teams supported by efficient 7 technical facilities and support services. The Ubiquitin Family in Hematologic Malignancies team is headed by Guillaume Bossis and presently includes 5 senior researchers, 5 PhD students and 1 engineer.

Additional Information

The position is available starting Oct 1, 2022. Initial funding for 1 year renewable once is already available. Interested applicants should send their CVs, including research interests and contact information for two references.

We talk about it on Twitter!